DDInter1158 DDInter537
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).
Mesalazine {u} (Compound) binds {v} (Gene) ALOX5
ALOX5 {u} (Gene) is bound by {v} (Compound) Diclofenac
Mesalazine {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is downregulated by {v} (Compound) Diclofenac
Mesalazine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Diclofenac
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Mesalazine {u} (Compound) binds {v} (Gene) ALOX5
ALOX5 {u} (Gene) is associated with {v} (Disease) and {u} (Gene) is upregulated by {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is palliated by {v} (Compound) Diclofenac
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Diclofenac
Mesalazine {u} (Compound) downregulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is associated with {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Diclofenac
Mesalazine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Clonidine
Clonidine {u} (Compound) resembles {v} (Compound) Diclofenac
Mesalazine {u} (Compound) causes {v} (Side Effect) Eye pain
Eye pain {u} (Side Effect) is caused by {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Diclofenac
Mesalazine (Compound) binds ALOX5 (Gene) and ALOX5 (Gene) is bound by Diclofenac (Compound)
Mesalazine (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is downregulated by Diclofenac (Compound)
Mesalazine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Mesalazine (Compound) binds ALOX5 (Gene) and ALOX5 (Gene) is associated with rheumatoid arthritis (Disease) and ALOX5 (Gene) is upregulated by rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Diclofenac (Compound)
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Nepafenac (Compound) and Nepafenac (Compound) resembles Diclofenac (Compound)
Mesalazine (Compound) downregulates TNIP1 (Gene) and TNIP1 (Gene) is associated with systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Diclofenac (Compound)
Mesalazine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Clonidine (Compound) and Clonidine (Compound) resembles Diclofenac (Compound)
Mesalazine (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Nepafenac (Compound) and Nepafenac (Compound) resembles Diclofenac (Compound)